Clinical trial NCT04244877 - References

Cirrhosis, Liver — Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility

Citation(s)

•   Allampati S, Duarte-Rojo A, Thacker LR, Patidar KR, White MB, Klair JS, John B, Heuman DM, Wade JB, Flud C, O'Shea R, Gavis EA, Unser AB, Bajaj JS
  Diagnosis of Minimal Hepatic Encephalopathy Using Stroop EncephalApp: A Multicenter US-Based, Norm-Based St
•   Bajaj JS, Heuman DM, Wade JB, Gibson DP, Saeian K, Wegelin JA, Hafeezullah M, Bell DE, Sterling RK, Stravitz RT, Fuchs M, Luketic V, Sanyal AJ
  Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encepha
•   Bauer TM, Schwacha H, Steinbruckner B, Brinkmann FE, Ditzen AK, Kist M, Blum HE
  Diagnosis of small intestinal bacterial overgrowth in patients with cirrhosis of the liver: poor performance of the glucose breath hydrogen test. J Hepatol. 2000 Sep;33(3):382-6. doi: 10.1016/s0168-8278(00)80273-1.
•   Chander Roland B, Garcia-Tsao G, Ciarleglio MM, Deng Y, Sheth A
  Decompensated cirrhotics have slower intestinal transit times as compared with compensated cirrhotics and healthy controls. J Clin Gastroenterol. 2013 Nov-Dec;47(10):888-93. doi: 10.1097/MCG.0b013e31829006bb.
•   Fein BI, Holt PR
  Hepatobiliary complications of total parenteral nutrition. J Clin Gastroenterol. 1994 Jan;18(1):62-6. doi: 10.1097/00004836-199401000-00015.
•   Giannelli V, Di Gregorio V, Iebba V, Giusto M, Schippa S, Merli M, Thalheimer U
  Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis. World J Gastroenterol. 2014 Dec 7;20(45):16795-810. doi: 10.3748/wjg.v20.i45.16795.
•   Groeneweg M, Quero JC, De Bruijn I, Hartmann IJ, Essink-bot ML, Hop WC, Schalm SW
  Subclinical hepatic encephalopathy impairs daily functioning. Hepatology. 1998 Jul;28(1):45-9. doi: 10.1002/hep.510280108.
•   Gupta A, Dhiman RK, Kumari S, Rana S, Agarwal R, Duseja A, Chawla Y
  Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. J Hepatol. 2010 Nov;53(5):849-55. doi:
•   Kakiyama G, Pandak WM, Gillevet PM, Hylemon PB, Heuman DM, Daita K, Takei H, Muto A, Nittono H, Ridlon JM, White MB, Noble NA, Monteith P, Fuchs M, Thacker LR, Sikaroodi M, Bajaj JS
  Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol. 2013 May;58(5):949-55. doi: 10.1016/j.jhep.2013.01.003. Epub 2013 Jan 16.
•   Maheshwari A, Thuluvath PJ
  Autonomic neuropathy may be associated with delayed orocaecal transit time in patients with cirrhosis. Auton Neurosci. 2005 Mar 31;118(1-2):135-9. doi: 10.1016/j.autneu.2005.02.003.
•   Pande C, Kumar A, Sarin SK
  Small-intestinal bacterial overgrowth in cirrhosis is related to the severity of liver disease. Aliment Pharmacol Ther. 2009 Jun 15;29(12):1273-81. doi: 10.1111/j.1365-2036.2009.03994.x. Epub 2009 Mar 6.
•   Quigley EM, Stanton C, Murphy EF
  The gut microbiota and the liver. Pathophysiological and clinical implications. J Hepatol. 2013 May;58(5):1020-7. doi: 10.1016/j.jhep.2012.11.023. Epub 2012 Nov 23. No abstract available.
•   Randolph C, Hilsabeck R, Kato A, Kharbanda P, Li YY, Mapelli D, Ravdin LD, Romero-Gomez M, Stracciari A, Weissenborn K; International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN)
  Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines. Liver Int. 2009 May;29(5):629-35. doi: 10.1111/j.1478-3231.2009.02009.x. Epub 2009 Mar 19.
•   Saad RJ, Hasler WL
  A technical review and clinical assessment of the wireless motility capsule. Gastroenterol Hepatol (N Y). 2011 Dec;7(12):795-804.
•   Shawcross DL, Wright G, Olde Damink SW, Jalan R
  Role of ammonia and inflammation in minimal hepatic encephalopathy. Metab Brain Dis. 2007 Mar;22(1):125-38. doi: 10.1007/s11011-006-9042-1.
•   Sidhu SS, Goyal O, Mishra BP, Sood A, Chhina RS, Soni RK
  Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial). Am J Gastroenterol. 2011 Feb;106(2):307-16. doi: 10.
•   Simren M, Stotzer PO
  Use and abuse of hydrogen breath tests. Gut. 2006 Mar;55(3):297-303. doi: 10.1136/gut.2005.075127.
•   Thalheimer U, De Iorio F, Capra F, del Mar Lleo M, Zuliani V, Ghidini V, Tafi MC, Caburlotto G, Gennari M, Burroughs AK, Vantini I
  Altered intestinal function precedes the appearance of bacterial DNA in serum and ascites in patients with cirrhosis: a pilot study. Eur J Gastroenterol Hepatol. 2010 Oct;22(10):1228-34. doi: 10.1097/MEG.0b013e32833b4b03.
•   Zhang Y, Feng Y, Cao B, Tian Q
  Effects of SIBO and rifaximin therapy on MHE caused by hepatic cirrhosis. Int J Clin Exp Med. 2015 Feb 15;8(2):2954-7. eCollection 2015.

Evaluation of the Therapeutic Effect of Rifaximin on Covert Hepatic Encephalopathy With Underlying Small Intestinal Bacterial Overgrowth and Gastrointestinal Dysmotility in Liver Cirrhosis Patients

Details for clinical trial NCT04244877